Regenxbio Inc (RGNX)
9.59
+0.41
(+4.47%)
USD |
NASDAQ |
Nov 22, 16:00
9.60
+0.01
(+0.10%)
After-Hours: 20:00
Regenxbio Revenue (Annual): 90.24M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 90.24M |
| December 31, 2022 | 112.72M |
| December 31, 2021 | 470.35M |
| December 31, 2020 | 154.57M |
| December 31, 2019 | 35.23M |
| December 31, 2018 | 218.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 10.39M |
| December 31, 2016 | 4.589M |
| December 31, 2015 | 7.588M |
| December 31, 2014 | 6.12M |
| December 31, 2013 | 6.087M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
35.23M
Minimum
2019
470.35M
Maximum
2021
172.62M
Average
112.72M
Median
2022
Revenue (Annual) Benchmarks
| Catalyst Pharmaceuticals Inc | 398.20M |
| EyePoint Pharmaceuticals Inc | 46.02M |
| Cassava Sciences Inc | -- |
| Vertex Pharmaceuticals Inc | 9.869B |
| Sarepta Therapeutics Inc | 1.243B |